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Abstract
Background: Accurate measurement of CD4 cell counts remains an important tenet of clinical care for people living
with HIV. We assessed an instrument-free point-of-care CD4 test (VISITECT® CD4) based on a lateral flow principle,
which gives visual results after 40min. The test involves five steps and categorises CD4 counts as above or below 350
cells/μL. As one component of a performance evaluation of the test, this qualitative study explored the views of
healthcare workers in a large women and children’s hospital on the acceptability and feasibility of the test.
Methods: Perspectives on the VISITECT® CD4 test were elicited through in-depth interviews with eight healthcare
workers involved in the performance evaluation at an antenatal care facility in Johannesburg, South Africa. Audio
recordings were transcribed in full and analysed thematically.
Results: Healthcare providers recognised the on-going relevance of CD4 testing. All eight perceived the VISITECT® CD4
test to be predominantly user-friendly, although some felt that the need for precision and optimal concentration in
performing test procedures made it more challenging to use. The greatest strength of the test was perceived to be its
quick turn-around of results. There were mixed views on the semi-quantitative nature of the test results and how best
to integrate this test into existing health services. Participants believed that patients in this setting would likely accept
the test, given their general familiarity with other point-of-care tests.
Conclusions: Overall, the VISITECT® CD4 test was acceptable to healthcare workers and those interviewed were
supportive of scale-up and implementation in other antenatal care settings. Both health workers and patients will need
to be oriented to the semi-quantitative nature of the test and how to interpret the results of tests.
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Background
From the earliest days of HIV care and treatment, CD4
cell count measurements have played a central role in
the care of HIV-infected children and adults. CD4
counts are an accurate predictor of disease status and
the immediate risk of death, and are thus used for iden-
tifying those who have advanced HIV disease and whose
care needs to be prioritised [1]. Over the past decade,
antiretroviral therapy (ART) in HIV-positive patients has
been initiated at progressively higher CD4 counts [2].
World Health Organization (WHO) guidelines increased
the ART initiation threshold from 200 to 350 cells/μL in
2010, to 500 cells/μL in 2013, and then in 2015, recom-
mended treatment for all HIV-infected patients, irre-
spective of CD4 count [2, 3]. This significant shift in
treatment protocols has unfolded against the back-
ground of ambitious UNAIDS treatment targets of
“90-90-90 by 2020”, and has brought the ongoing rele-
vance of CD4 testing into focus [4].
CD4 measurement is still included in WHO and na-
tional guidelines in South Africa and other countries as
part of the battery of tests done prior to ART initiation
[5–8]. In this instance, CD4 testing informs the prioritis-
ing of ART initiation in patients with a CD4 ≤ 350 cells/
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μL, and determines the need for opportunistic infection
prophylaxis (at a CD4 count of ≤200 cells/μL) and for
testing for cryptococcal antigenaemia (at a CD4 count of
≤100 cells/μL) [6]. Further, WHO recommends that, in
settings where HIV viral load (VL) testing is not rou-
tinely available, a CD4 count should be done 6-monthly
in patients receiving antiretroviral treatment. These test
results, interpreted in conjunction with clinical monitor-
ing and a patient’s history of drug adherence, are used to
diagnose treatment failure [9]. Though VL testing is in-
creasingly available, only about half of the estimated 20
million people receiving ART worldwide have access to
it [10]. Where VL testing is available, CD4 count moni-
toring can be reduced in frequency or stopped, in those
who are stable on ART and are virally suppressed. Pa-
tients with unstable or advanced HIV disease still re-
quire CD4 monitoring, however, even when VL testing
is readily available [7].
Flow cytometric methods have been the gold standard
for CD4 monitoring since the beginning of the HIV epi-
demic, but these methods require specialised electronic
instruments, and typically need constant power or
batteries, intensive quality control procedures, as well as
highly-trained laboratory staff [11]. These requirements
have constrained CD4 testing in a number of
resource-constrained settings, but especially for rural
populations [12–15]. Moreover, patients in many coun-
tries lack a unique patient number, making it very diffi-
cult to trace test results from different laboratories,
especially in patients referred between hospitals and
clinics. In one study in Mozambique, Malawi, and South
Africa, as many as 50% of CD4 test results were not
returned to the clinics [16]. Testing at the point of care
(POC) may overcome many of these access barriers and
enable poorly resourced and remote facilities to
prioritize patients for ART eligibility and monitor their
ART responses more effectively.
POC CD4 testing may also be more cost-effective than
laboratory-based methods [17, 18]. It has been found to
facilitate timely decision-making and care linkages, and
help improve patient care and retention in most studies
[12, 13, 19, 20], but not all [21, 22]. To date, all POC
CD4 tests have required an instrument [23–25], thus in-
curring many of the limitations of machines in central
laboratories, including frequent error codes, technical
breakdown, and lack of access to technical support [26,
27]. The Burnet Institute has developed a POC CD4 test
that can be used without an instrument (VISITECT®
CD4, Omega Diagnostics, UK) [28], based on a lateral
flow principle, which gives visual results after 40 min
(Fig. 1) [29].
Understandably, much of the research focus around
the development of CD4 diagnostics has centred on the
validity of the test [12, 27, 30]. Inaccurate measures of
CD4 cell count can have important consequences, espe-
cially if patients are misclassified as having treatment
failure, or missed when their treatment has, in fact,
failed. While test validity clearly warrants attention, fac-
tors such as end-user perspectives, effect on patient flow
within the clinic, and the fit with user needs are also
Fig. 1 VISITECT®CD4 test strip
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important [31]. However, the views of healthcare workers
who perform the tests and, ultimately, of patients them-
selves have seldom been examined. Even more rarely are
qualitative methods used in such evaluations [26, 32, 33].
We report here on a qualitative study that formed one
component of a Field Testing study, in which the validity
of VISITECT® CD4 was evaluated within an antenatal
clinic in South Africa, and before the device obtained
CE marking (November 2017) [34]. Our aim was to pro-
vide an in-depth understanding of the views of health-
care workers on the acceptability and feasibility of rapid,
POC CD4 testing in this clinical setting. The findings
may have broader relevance for those developing similar
POC diagnostic tools, and for health communication
specialists who have an interest in designing appropriate
education and training materials for healthcare workers
and patients alike.
Methods
Study setting and routine care
Rahima Moosa Mother and Child Hospital (RMMCH) is
a tertiary-level public sector hospital in Johannesburg.
Women attending the hospital are either locals from
surrounding areas or high-risk cases referred from other
antenatal clinics in the region. The HIV prevalence
among women giving birth at the hospital is estimated
to be in the region of 25% [35]. The programme for pre-
venting mother-to-child transmission (PMTCT) of HIV
infection is well established and has been progressively
strengthened over time [36–38]. Current rates of HIV
transmission from mother to infants are 1.6% [35]. CD4
cell count testing is routinely performed at the first ante-
natal visit for all pregnant women with HIV, and blood
samples are sent to an external quality-controlled la-
boratory for CD4 count testing using standard flow cy-
tometry methods. The turn-around time for results from
laboratory to antenatal clinic is between 1 and 3 days.
Patients only receive results when they return to the
hospital for their subsequent antenatal care visit or to
give birth. Viral load testing is available at the site and
used to detect antiretroviral treatment failure.
Study design
In April 2017, the perspectives of a small group of
healthcare workers at RMMCH were elicited using
in-depth, semi-structured interviews. These were health-
care workers who had engaged with the VISITECT®
CD4 test during the Field Testing study, either in the
hospital laboratory or in the antenatal clinic. Participants
were interviewed individually to allow for detailed dis-
cussion of specific experiences with the test among di-
verse levels of health workers. Qualitative data were not
collected from patients themselves as they had not been
given the results of the VISITECT® CD4 test, instead
only receiving the flow cytometric CD4 testing, as per
standard of care.
VISITECT® CD4 testing procedures
Blood samples were collected using both capillary tubes
from a finger prick and by venepuncture. Venous sam-
ples were tested in the hospital laboratory as well as at
the point of patient care, while finger prick samples were
tested only at the point of care. In the first step of the
test, 30 μL of blood was applied to the test strip, and
buffer solution added to the strip after 3 min and again
17min thereafter. The test result was read 20 min later
(40 min in total; see Fig. 2).
The test strips were read both visually and with the
use of a hand-held electronic reader (VISITECT® CD4
Reader). The test is semi-quantitative, with visual results
in the form of a line on the strip, similar to that seen on
a pregnancy test. The line indicates whether the patient’s
CD4 count is above or below the set threshold of 350
cells/μL (Fig. 1). Three months prior to the study enrol-
ment, healthcare workers attended 2 days of training on
study procedures and completed practical sessions with
the device. Following completion of the first 50 practice
tests, a refresher training was repeated immediately prior
to the onset of the study.
Participant selection and interview
For the qualitative sub-study, all eight health workers
who had been directly involved in the project were
invited to participate in interviews. All agreed to be
interviewed. Participants included a diverse range of
healthcare workers, namely: two counsellors, three regis-
tered nurses, one medical officer, one phlebotomist and
a laboratory worker. The medical officer and the three
nurses were based in the hospital’s Research Unit, while
the laboratory worker was stationed in a small laboratory
dedicated to research activities. Both counsellors worked
in the antenatal clinic and the phlebotomist was based
in the postnatal ward but also collected blood samples
from the antenatal clinic. All but one of the participants
were female, and the number of years they had been
working in their current position ranged from two to 23
years, with a median of 7.5 years.
Participants were interviewed by a member of the
study team who is a qualitative social scientist (FS). All
interviews took place in a private room within the hos-
pital. A semi-structured interview guide was developed
following discussion among members of the study team,
which included researchers who had been involved in
training for the field testing study and the product devel-
opers (Additional file 1: Interview Guide). The guide in-
cluded open-ended questions on the following themes:
healthcare workers’ perceptions of the role of CD4
testing; experiences of using VISITECT® CD4 and
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acceptability of the test; perceptions of the validity of the
test; and views on obtaining semi-quantitative results.
Interviews were in English and lasted between 35 min
and 1 h each. All were audio-recorded.
Data management and analysis
Audio recordings were transcribed by a transcription
service and checked by the interviewer to ensure fidelity
to the recordings. Using a grounded theory approach
[39], the transcripts were then reviewed and inductively
coded according to emerging themes. These themes
were used to develop a matrix that allowed for compari-
son of key themes across all participant transcripts and
the identification of patterns in the data [40]. Data ana-
lysis was led by the interviewer, who discussed key
themes and interpretation of findings with the rest of
the study team. Text for the paper was then constructed
on the basis of this completed matrix. Participant quotes
were selected to illustrate key findings from the analysis.
Results
Importance of CD4 testing
Even in the era of ‘test and treat’, all participants inter-
viewed for the study felt that CD4 count testing
remained an important diagnostic and monitoring test
in this setting. They cited the need for a CD4 ‘baseline’
Fig. 2 Timing and procedures for each step of the VISITECT® CD4 test
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for patients initiating ART and they felt that ongoing
CD4 monitoring was required to measure the need for
OI (opportunistic infection) prophylaxis, ART response
and a switch in treatment regimens.
However, the view of some participants – mainly the
nurses and the medical officer – was that increasingly,
VL measurements were used for monitoring patients’
progress.
In the clinics we focus on looking at their viral load
instead of the CD4 count. But, then it’s still important
to check the CD4 count because… are the cells in the
blood becoming strong? [Nurse].
As the nurse’s comment suggests, these two measure-
ments were considered complementary and in need of
simultaneous appraisal. CD4 count results were also
regarded as a useful marker to alert healthcare workers
to possible adherence failures, even becoming vital infor-
mation to motivate patients to adhere.
So when she knows exactly what is going on in her
body [after having a CD4 test], yes; it is a good
motivation. She would want her CD4 to go up.
[Nurse].
Participants also noted that patients generally have a
good understanding of CD4 testing and the role that
CD4 cells play in relation to HIV. They attributed this to
the substantial counselling and education that patients
have received in HIV Counselling and Testing (HCT)
settings and in ART clinics in recent years. Conse-
quently, many patients have a strong desire to know
their CD4 count results.
The only thing that they are worried about is the CD4
count, because everybody has been saying, CD4 count,
CD4 count… [Counsellor].
Acceptability of rapid tests for CD4 testing
User-friendliness
Overall, the VISITECT® CD4 was regarded by all health-
care workers interviewed as an “easy” test to perform,
generating results that were “easy” to read. Both the la-
boratory worker and the phlebotomist emphasised the
“straightforwardness” of VISITECT® CD4 test proce-
dures, and their familiarity given prior experience in
using other rapid POC tests that require finger pricks,
such as the rapid pregnancy test and rapid HIV antibody
tests.
So, if you know how to do the reading visually, then I
don’t think there should be a problem. If it’s accurate,
then it will be a pleasure to work with this kind of test.
It’s straightforward, it’s easy, it’s not time consuming.
[Laboratory Worker].
After further probing about specific aspects of the test,
participants drew attention to what they had experi-
enced as a very small margin for error in performing it.
As they described it, the set-up was quite unforgiving in
its demand for precision in each of the test’s five seg-
ments or steps (Fig. 2), which made it less user-friendly
as a result.
There seems to be an absolute need to run this
perfectly, in the lab when you run the test, as in not
35 μl, not 25 μl, but 30 μl of blood. And so who knows
what, with the mixing and all the little things… The
time has to be exact... No, I mean if you’re not
dedicated to it and you come a few minutes late
because you’re busy with something else... it makes one
worry. [Medical Officer].
In practice, this meant that those performing the test
needed focused concentration and minimal interruptions
to avoid errors or miscalculations in the timing and
completion of each step. Participants who had some ex-
perience in collecting blood samples and applying them
to the test strips advised that it was essential to develop
a “system” to ensure correct performance of each of the
five steps. A nurse phrased this as needing to “structure
it nicely”, while a counsellor stressed it was important to
shut out other distractions and “be focussed”. Import-
antly, the time lag between some steps, as much as 20
min between steps 4 and 5, meant that most healthcare
workers tried to multi-task and make productive use of
this wait. These attempts were only partially successful:
some found the multi-tasking too distracting, thus en-
dangering their ability to return to the test strip in time.
One participant found this need for precision to be
stressful and believed that, if done at the ‘bedside’, it
could interfere with the quality of counselling.
… you are losing focus here and you don’t want to
leave this patient unattended as well, because there
are things that she needs to know, maybe about,
regarding the CD4 count, the viral load, and once you
neglect the patient as well, it’s a problem. [Counsellor].
To some extent, perceptions of user-friendliness
depended on where in the facility the test would be posi-
tioned and who would actually be responsible for per-
forming it. Those who found it challenging to multi-task
within a clinical environment believed that the test was
best handled in the laboratory. Alternatively, to resolve
the dilemma of how to perform a test that requires
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concentration and focus, while at the same time man-
aging consultations with individual patients and juggling
other administrative duties, three participants felt that a
dedicated staff member should be tasked with perform-
ing the POC CD4 test.
If there’s one person who is allocated to do only this
job then it could work. Even with the nurses, you know,
I don’t see every nurse who sees a patient doing the
test. So there should be one person who has that role,
they do the test and they focus only on the test. Also, it
will minimise problems of errors happening. [Nurse].
Those who were not troubled by this need for focus
and precision tended to rely on two items that served as
aides-memoire: a timer with an alarm to signal the end
of each time segment, and a wall chart depicting the se-
quence and duration of each step. One nurse described
how these tools were used:
Somebody will be coming in… and I say okay wait, okay,
I need to set my timer, I’m waiting for the 17min to end
so that I can set up the next one. So, before that, I
cannot move from here. It’s a fairly easy test to run. You
just need to make sure that you’ve got your timer… You
always need to have that guide on the wall and keep
checking, keep checking. That helps. [Nurse].
One counsellor was puzzled by why multiple steps
were needed in the testing procedure at all, and called
for these to be reduced or collapsed into a single step:
The need of improvement is the time, because I am
really not sure why are we waiting 3 min and then the
17 min and then the 20, I don’t know why that is
happening [….] You know? Instead of doing the thing
at the same time, and see what it’s going to give us.
[Counsellor].
Closely related to the question of ease-of-use is the
concern about whether a new task added to a healthcare
worker’s scope of work would be perceived or experi-
enced as a workload burden – and therefore risk gener-
ating resistance to the task. Participants were asked to
imagine the VISITECT® CD4 test being added to their
current scope of work: what would that mean for them,
personally?
Overall, the responses were positive and the handling of
rapid CD4 count tests was not seen as necessarily imply-
ing an added burden to workloads. One of the counsellors
was cautious, however, remarking that “it will depend on
how many people we are seeing”, while another counsellor
considered the extra task manageable only if you were
“organised”.
Related to the question of scopes of work, participants
were asked which level of healthcare worker would be
best placed to administer the VISITECT® CD4 test,
should it be integrated into routine care in antenatal set-
tings. Assuming the blood sample would be drawn from
a finger-prick rather than by venepuncture, two of the
nurses believed that administrating the test would fit
well within a counsellor’s scope of work and skill-level.
As one put it,
I don’t foresee any problems if the counsellor actually
does the whole process, but it will mean proper
supervision and making sure that every step goes very
well. [Nurse].
This idea was supported by the counsellors them-
selves. Citing the unique focus and skills of counsellors
working in an environment with many HIV-positive pa-
tients, they claimed the test could serve to further ex-
tend the patient-centred care they provide:
I think the counsellor is the best person to do that,
because already they are going to have that
relationship, they are going to have that interaction,
they would have spoken about the CD4 count as
well… you are talking about treatment, you are talking
about the viral load and everything. So you would
have aligned everything, and then you are going to say
now you are going to do this [test], okay. [Counsellor].
Turn-around time
Presently, counsellors in the ANC clinic record the
names of all patients awaiting CD4 count results in a
register as part of standard care, and then follow up a
few days later to record the results as they are received
from the central laboratory. The relevant healthcare
workers review these results as a team, and a decision is
made about which results are concerning enough to
warrant the patient being called back to the clinic earlier
than their next scheduled visit. These patients are then
phoned and requested to return to the clinic promptly.
The counsellor who explained this process maintained
that, “for me, it’s not working”. The time lag between
test administration and conveying of results to the pa-
tient, she felt, was too long. Furthermore, some patients
never received their CD4 count results because they did
not return to the facility, possibly because they feared
that these results might signal deteriorating health.
In theory, the introduction of POC CD4 testing would
alleviate this concern, eliminating the need for counsel-
lors to follow-up and check that all results had been
returned from the laboratory. Undoubtedly, participants
saw this as the greatest strength of the test: CD4 count
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results could be relayed to the patient immediately and
decisions about follow-up treatment be made there and
then. The test was regarded as valuable in terms of im-
proving continuity of care, but cost savings were also
mentioned as a positive off-spin.
Another thing that I would like to add on, mina [me],
I would just say a big “up” to this test, we can use it,
it’s going to save us money, it’s going to save the
patient a trip, it’s going to save the patient a whole lot
of things, you know. [Counsellor].
A number of participants believed the time-saving di-
mension of the VISITECT® CD4 test would help in par-
ticular to alleviate patients’ anxieties about their health.
Most of the patients that I have come across, they
become so worried – ‘I think I am getting sick and
maybe my CD4 count has dropped’. So with that giving
them their results immediately and with them knowing
whereabouts, it really makes a lot of difference […]
unlike having to wait for the next visit. [Nurse].
But a quick turn-around had benefits also for health-
care workers themselves. One counsellor pointed out
that the absence of an immediate CD4 result made it
harder for them to offer tailor-made counselling to the
patient. She described the impact of such efficiencies: “it
will make me feel great, that this woman is going to go
home knowing exactly what is happening with her”.
Similarly, a nurse recounted how a doctor (not in-
volved in the study) had witnessed her administering a
VISITECT® CD4 test and had asked what she was doing.
The nurse had explained the study and how the VISI-
TECT® CD4 test kit worked.
And she [the doctor] said ‘This would be great when
we have our patients in front of us, and we need an
indication now, of where the patient is… ‘Okay, let’s do
a CD4, quickly and let’s see where you are.’ [Nurse].
Overall, most participants felt that adding a POC CD4
cell count test to their repertoire of monitoring tools
would strengthen the package of care currently offered
to patients.
They [mothers] would be happy to know when they
leave, this is my CD4 count, ... because you always tell
them during counselling that we don’t only want your
baby to be alive, but we want you to be around for
your baby. So it actually gives us a full package when
taking care of the mother and taking care of the baby.
So to me, that is a huge advantage. [Phlebotomist;
emphasis added].
All were supportive of the VISITECT® CD4 test being
scaled up and implemented in antenatal settings around
the country, once fully approved. Implementation was
recommended, in particular, in large antenatal clinics
and labour wards where there were likely to be many pa-
tients who had not attended antenatal care and thus had
an unknown HIV status and CD4 count. Participants
also saw a role for the test in “normal routine clinics,
where they are doing the rapid tests, HIV tests, [and] in
the mobile clinics” [Counsellor], as well as “in ARV clinics”
[Nurse]. Health facilities in especially resource-poor areas
and those located some distance from large urban centres
were identified as sites where rapid CD4 count testing
would be particularly useful.
Especially in... the rural areas, bloods get sent away.
Many times, bloods get lost in transit or when it goes
to the main lab, there’s always the human error
sometimes, wrong hospital numbers, wrong names, you
know the results are there but they just can’t find it. So
I think this [VISITECT® CD4] will be useful. Definitely.
[Laboratory Worker].
Reliability and accuracy
Study participants were given the hypothetical options
of 70 and 90% accuracy and asked which level they con-
sidered to be ‘good enough’. Most regarded 90% as the
minimum level acceptable:
Well, nothing is 100% accurate [laughs], but I would
still go for it, because I feel that it is... the HIV test and
all the other tests that use the same process, I don’t
think they are like 100% most of the time, so if it’s
90%, it’s good enough. [Phlebotomist].
In an attempt to put accuracy issues in context, the
medical officer emphasised the importance of the test
not missing “the low ones” – patients with very low CD4
counts, who needed urgent intervention. Linked to this,
he raised the potential for the test to serve as a screening
mechanism, where, for example, patients who registered
a CD4 count below 350 would go on to have a confirma-
tory flow cytometry test in the laboratory.
Although explored only indirectly, the interviews did
address the question of whether healthcare workers
thought patients themselves would trust the results of
rapid POC tests. Participants thought some patients pre-
ferred tests to be performed in front of them, rather than
having the sample sent away to a laboratory, where errors
could happen and patients would be none the wiser.
Patients are used to this [rapid test], unlike something
you don’t see, when it goes to the lab and when it
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comes back, you can always think, maybe they made a
mistake. But if you’re there, you can see it happening.
[Phlebotomist].
Generally, health workers believed that all POC tests –
not only VISITECT® CD4 – were vulnerable to ques-
tions about accuracy. Where inaccuracies arose, there
were obvious consequences for patients, but also for
healthcare workers. Several participants made it clear
that they did not want to work with unreliable tests,
which they believed would undermine their confidence
in the workplace.
I wouldn’t have the confidence to be saying what I’m
saying, you know, I would be mumbling and… then I
would be hoping that there isn’t that person who
would be asking me, you know, difficult questions…
because if I am in that scenario I would not be able to
tell false information; I’ve got to say it as it is. And if
I’m looking at you and I’m saying this test is not
reliable, I mean, you know... [Nurse].
In short, there was a strong emphasis on the import-
ance of healthcare workers being able to trust the diag-
nostic tools they were using.
Eye versus machine: Views on the VISITECT® CD4 reader
There were mixed views on whether a visual read-out of
the test result was more or less reliable than obtaining a
reading from the CD4 Reader that was used in the Field
Testing study. The laboratory worker – who, out of all
participants, had the most experience of using both
methods – had this to say of the CD4 Reader:
The instrument itself, it’s such a small machine, and it’s
very user-friendly. The machine should tell you what to
do, what the next step is. So I think it’s a great machine.
And I would go for this in the lab. [Laboratory Worker].
The majority were adamant that the Reader generated
the most reliable results, even if they did not have direct
experience of using it. This belief seemed to come from
a deep-seated trust in the credibility of electronic tech-
nology in general.
I think we now have a reading eye, we do now have a
reading eye. [laughs] But I will believe the machine… I
think the machine is less stressful, because with the
eye… you’re reading and reading and you think, ‘it’s
even’. If it’s even it might be below? …So, I won’t trust
the eye. [Counsellor].
This reference to a “reading eye” came up in other in-
terviews, where participants spoke of the confidence in
doing visual read-outs that develops with experience.
About a third of the participants claimed they actually
trusted their visual interpretation of the test strip more
than the Reader-generated result, one saying:
On the strip it will be clear that it’s below or it’s above.
But then when you put it in the reader it gives you
something else. It’s not all the time. So now I said no,
you know what? My eyes are not playing tricks on me.
It is that high, so it’s above. I’m sticking to that.
[Nurse].
Views on the semi-quantitative nature of VISITECT® CD4
Participants were divided on the acceptability of the
semi-quantitative nature of the VISITECT® CD4 test
(where the result is ‘above’ or ‘below’ a certain threshold,
rather than an exact number). One disadvantage of the
semi-quantitative calibration, according to most partici-
pants, was that it did not allow for ‘borderline’ cases to
be distinguished. The laboratory worker explained the
problem thus:
If my machine tells me I’m above 350, what if it’s just
borderline, where it’s just 350? And if it tells me I’m
below 350, what if it’s 349? …So I still think that if we
could get an exact reading, that would be great, you
know? … We should know the exact value. [Laboratory
Worker].
Similarly, a semi-quantitative test could not tell you
how far below or above the cut-off level a patient’s CD4
count was. As a nurse explained,
I think it’s a problem because now, you know, it says
below 350 so you could be 340 or you could be 20… So
it doesn’t really give you a feel of where is this patient.
I want the numbers. [Nurse].
Participants were quick to distinguish between their
own preferences on this issue and those of their patients.
Most indicated that – as healthcare workers – they did
not necessarily need an exact number. One nurse de-
scribed how she conveyed and explained CD4 count re-
sults to her patients by referring to a wall chart that
allowed her to pinpoint the result in relation to the 350
cells/mm3 threshold:
What’s important is being above 350. They’re going to
pray to be above 350. And even though, I mean, you’re
going to show them. This is the line. And your CD4, it’s
above…So, if we’re giving them results, then we can
say, you know, this is your line, this is where you fall.
On that chart. [Nurse].
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Similarly, several participants said that when commu-
nicating CD4 count results to patients, they tended to
use only the terms “high” or “low”, even when exact
numbers were available. Most, however, recognised that
a more precise measurement of CD4 count was at times
important for patients as it helped them to monitor and
understand their progress more accurately. In other
words, one could be told that one’s CD4 count was
“above 350”, but some patients then wanted to know:
how far above 350? Receiving an exact number.
…gave them that satisfaction to know that they are
doing very well. So knowing the value actually makes
a big difference. [Nurse].
Finally, there was even a suggestion that a
semi-quantitative test had some advantages over a purely
quantitative test, as over time it could help to lessen pa-
tients’ ‘fixation’ with a number and the anxiety that inevit-
ably arose when that number changed, even marginally.
With the CD4 count, people are used to getting a number
and a clear CD4 count. People will still ask, you know,
“my CD4 dropped from 800 to 600 and what does that
mean?” and they get anxious about that, start to worry a
lot about it. So it [a semi-quantitative test] might reduce
some of those anxieties…in that it doesn’t get people too
worried about the level change. [Medical Officer].
Communicating test procedures and results to patients
Participants were asked to consider how they would ac-
tually communicate the purpose of the VISITECT® CD4
test, and the less-than-100% accuracy of the results in
particular, to their patients. Again, the visual similarity
between the VISITECT® CD4 test-kit and other POC
tests – such as the rapid HIV test – made this task
much easier.
One thing I like about this kit, is it’s familiar to them.
Because they know the strips – because of the HIV
[rapid antibody] test. [Phlebotomist].
One participant suggested that future implementation
of the VISITECT® CD4 test in clinical settings might
benefit from being accompanied by ‘job aids’ – like flip
charts – that make use of visual diagrams and illustra-
tions to communicate complex concepts to patients.
I think what would be great for this study, if it gets
implemented, is having diagrams. Simple diagrams,
with, like, I draw Xs and Os in my blood vessels. So
the Xs are the viral load and the Os are the CD4. And
if you take your treatment, this is what it will look
like. And you know, your CD4 has to look like this,
then. Simple things… Just because people are better off
if you show them. [Nurse].
Participants were unanimous in believing that patients
should be made aware of the fact that results from a
CD4 POC test could never be 100% accurate. Various
approaches to communicating this to patients were
favoured. One suggested explaining that what was more
important than perfect diagnostic accuracy was the clin-
ical judgement applied by healthcare workers, which in-
volved ‘erring on the side of caution’ anyway in order to
protect patients’ health:
….the general sense of hey, this [test] shows us this, but
it’s not 100%. But if it shows lower, chances of it being
lower are high and we’d rather give you some
protection [prophylaxis]. [Medical Officer].
Others framed the openness about test accuracy in
terms of the responsibility to be accountable to patients.
I think it’s important, in case… the test did go wrong
somewhere, we’re able to go back to them with a
straight face and say, you know, like we said, there was
a 90% chance that it was accurate, we found that
there was fault with it. But it would be easier to say
that for accountability reasons. [Phlebotomist].
Finally, there was one suggestion that – should the test
be administered by counsellors or nurses as part of their
battery of routine tests performed on antenatal patients
– it could actually be viewed as an opportunity to im-
prove patient care in somewhat creative ways. It was the
hope of the medical officer that the additional time
needed in each patient consultation to administer the
rapid CD4 count test and wait for results could be used
to improve the quality and quantity of counselling of-
fered to a patient, that it would become.
…part of the proper understanding of patients and not
just an extra burden which will make the sisters more
frustrated and less empathetic…. And so it can be
done in that context of spending enough time with
people… I guess it doesn’t really solve the issue of levels
of communication and quality of communication to
the patients, but…hopefully one would study it further
and link it with that element, not just doing a
technical thing. [Medical Officer].
Discussion
Findings from our study address a key gap in evidence
as few studies have applied qualitative methods to
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examine the acceptability and feasibility of POC CD4
testing among healthcare workers [26]. Although use of
CD4 count measurements to determine ART eligibility
has declined in a number of countries, CD4 tests remain
important for triaging care at the time of HIV diagnosis
and thereafter [3]. In this qualitative study of the per-
spectives of healthcare workers in a South African ante-
natal setting, CD4 cell count testing was considered to
have continued relevance, most notably for establishing
a ‘baseline’ for patients initiating ART, monitoring treat-
ment progress and overall patient wellbeing. In assessing
the VISITECT® CD4 test, participants considered its
greatest strength to be its quick turnaround of results
and cost-saving potential, both for patients and health
services. This has been reported elsewhere in relation to
POC CD4 testing more generally [41]. The quick
turn-around of results could expedite clinical decisions,
particularly about the initiation of OI prophylaxis [42].
This is especially important for specific groups of pa-
tients with high loss-to-follow-up rates. In this hospital
setting, patients referred from other facilities with in-
complete medical records were often lost to follow-up,
as were patients from outside South Africa presenting
for childbirth without having attended antenatal care.
Participants in our study also viewed the VISITECT®
CD4 test kit as ‘user-friendly’ and easy to use, at least
partly because of their familiarity with lateral flow tech-
nology, from using other POC tests, such as rapid HIV
antibody and pregnancy tests. VISITECT® CD4’s rapid
POC, instrument-free technology for measuring CD4
cell counts is therefore ideally placed for use in diverse
healthcare settings, including rural or remote areas and
in primary care facilities or community outreach, such
as in mobile clinics and other forms of community or
household campaigns [41, 43, 44].
The additional workload of performing rapid CD4
testing at point-of-care, in the absence of financial in-
centives or additional staffing, has been identified as a
major barrier to its introduction in clinical settings in
LMICs [26, 45]. Participants in our study revealed nu-
anced views on the question of additional workloads.
Overall, they did not regard adding the VISITECT® CD4
test to their scope of work as necessarily burdensome,
but expressed concern about the demand for precision
in performing the five steps of the testing procedure.
Concentration and avoidance of interruptions were ne-
cessary to avoid errors, and some anticipated that this
would impact negatively on patient care. It was sug-
gested that additional research be done to explore
whether the extra time required for the test in each pa-
tient consultation could be used to deepen counsellors’
rapport with patients and improve the quality of coun-
selling. Future guidelines will need to clarify the recom-
mended location within health facilities and the cadre of
healthcare worker most appropriate for conducting the
test; failure to do so may undermine test uptake [32].
It is possible that the VISITECT® CD4 assay is more
suited to implementation in laboratory settings (at least in
health facilities equipped with a laboratory) than at the
‘bedside’. Conducting the testing in an on-site laboratory
would not require a remote central laboratory or highly
specialised staff, and might address other healthcare
worker concerns about the need for precision and concen-
tration in administering the test [31, 41]. Testing away
from the ‘bedside’ could, however, potentially erode some
of the cost and time benefits of the test. An alternative to
relegating the test to the laboratory would be to assign full
responsibility for rapid CD4 count testing (possibly along
with other rapid POC tests) to a cluster of dedicated
healthcare workers. This strategy might also improve test
accuracy, given that performance of test procedures and
reading of results may improve with practice. In our study,
counsellors were widely regarded as being most suited to
perform the test and have successfully performed POC
testing elsewhere [46, 47].
Healthcare worker or patient preferences for finger
pricks over venous sampling would favour ‘bedside’ test-
ing. Interestingly, evidence of patients’ preferences for
finger prick collection as opposed to venepuncture is
mixed. One study showed that patients preferred finger
pricks mainly due to continued bleeding after venepunc-
ture [48] and because with finger pricks there was “no
suspicion that blood was used for other purposes” [49].
In another study, patients favoured venepuncture due to
concerns about the need for multiple pricks if sufficient
volume is not obtained in one prick [50]. Health workers
appear to generally favour venepuncture [26].
While there were mixed views on whether a visual
read-out of the test result was more reliable than a read-
ing from the CD4 Reader, healthcare workers inter-
viewed in our study were unambiguous in their
disavowal of tests with sub-optimal accuracy. In time,
they might consider such tests more analogous to cer-
vical cancer screening tests, such as Pap smears, which
need to be confirmed with more accurate, specialised
testing [51]. Communicating results when the test in
question has a relatively low sensitivity or specificity
would be difficult for healthcare workers. For patients
receiving such results, comprehension might be equally
challenging.
Views on the semi-quantitative nature of the VISITECT®
CD4 assay were also mixed, but broadly, this was consid-
ered acceptable. The limitations of a semi-quantitative
measure were most evident in patients with ‘borderline’
cases [48], and for determining the direction of a patient’s
progress or deterioration within the categories of ‘above’
or ‘below’ 350. For patients, an ‘exact number’ rather than
a binary higher or lower reading might assist them to
Scorgie et al. BMC Health Services Research          (2019) 19:123 Page 10 of 13
monitor and understand their progress more precisely.
Implementation of the test could be supported by pictorial
job aids (such as flip-charts) that help health workers to
explain the meaning of CD4 counts and communicate
VISITECT® CD4 test results to patients [32]. Giving pa-
tients written educational information after POC CD4
testing has been shown to raise retention in care in a trial
in South Africa [52].
The study has some limitations. Health workers were
assessing a test whose validity had not been ascertained
at the time of the study (CE marking obtained Novem-
ber 2017) [34]. The interviews, however, preceded as if
the device would work and be used in future. Partici-
pants, when formulating their response, were asked to
imagine that the test was actually being used in routine
care. Nevertheless, doubts about the test’s validity may
have influenced their perceptions of the test and its po-
tential contribution to patient care. Participants’ per-
spectives were based on having performed a limited
number of tests (an average of 150 each) and the study
was unable to measure whether their views would have
evolved over time as additional tests were done, or con-
ducted as part of routine patient care, as opposed to
within a discrete study in a research setting. Related to
this, the healthcare workers we interviewed were re-
search staff rather than public sector workers, implying
that their views on workload need to be appraised with
this in mind. Also, while assessing health workers’ per-
ceptions of POC CD4 testing adds to the existing body
of evidence, a more comprehensive ‘end-user’ assess-
ment would be valuable for capturing the perspectives of
patients and their understandings of the test, especially
its semi-quantitative nature.
Conclusions
In conclusion, assessing the CD4 cell count level following
diagnosis enables triaging of HIV disease stage, and could
improve ART initiation and retention rates [41, 43]. Pa-
tients with CD4 > 350 cells/μL may have improved
longer-term ART adherence if they undergo regular coun-
selling until ART readiness is confirmed [53]. The
instrument-free, point-of-care VISITECT® CD4 test can be
useful as a triaging device, allowing for the prioritization
of patients, both in facility- and community-based care
settings. This may be particularly useful in more remote
settings with limited or no access to laboratory-based test-
ing where CD4-based ART prioritization is still taking
place. The device may also have a role in the monitoring
of a patient’s response to ART.
The diverse range of health workers participating in
this study were all supportive of the VISITECT® CD4
test being scaled up and implemented in antenatal set-
tings around the country, once fully approved. Overall,
the VISITECT® CD4 test was acceptable to healthcare
workers, but questions remain about the optimum site
within health facilities for testing and how best to in-
corporate the test into healthcare workers’ existing
scopes of work. As the test is introduced in clinical set-
tings, healthcare workers will need to be oriented to
how to explain and understand rapid tests whose results
have some measure of uncertainty.
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